Autolus Therapeutics Plc · NASDAQ:AUTL
Autolus Therapeutics — Q1 2019 Earnings Presentation
18 slides from Autolus Therapeutics's earnings presentation, May 14, 2019
Slide 1: Financial Results and Operational Highlights for Q1 2019
NASDAQ: AUTL Financial Results and Operational Highlights for Q1 2019 May 14, 2019
Slide 2: Disclaimers
Disclaimers These slides and the accompanying oral presentation contain forward-looking statements, including statements about the Company's plans to develop and commercialize its product candidates, the Company's ongoing and planned clinical trials, the anticipated benefits of the Company’s product
Slide 3: Agenda for today
Agenda for today 1. Corporate Overview and Introduction: Dr. Christian Itin, Chairman and CEO 2. Operational Highlights: Dr. Christian Itin 3. Financial Results and Overview: Andrew J. Oakley, Chief Financial Officer 4. Upcoming Milestones and Conclusion: Dr. Christian Itin 5. Q&A: Dr. Christian Iti
Slide 4: Corporate Overview and Introduction
Corporate Overview and Introduction Dr. Christian Itin Chairman and CEO 4
Slide 5: Autolus pipeline
Autolus pipeline Product Indication Target Preclinical Phase 1/2 Phase 2/3 B Cell Malignancies AUTO1 Pediatric ALL CD19 UCL - CARPALL AUTO1 Adult ALL CD19 UCL – ALLCAR19 AUTO3 Pediatric ALL CD19 & CD22 AMELIA AUTO3 DLBCL CD19 & CD22 ALEXANDER AUTO3 NG B-Cell Malignancies Undisclosed Multiple Myeloma
Slide 6: Operational Highlights
Operational Highlights Dr. Christian Itin Chairman and CEO 6
Slide 7: Pipeline and product updates
Pipeline and product updates ➢ AUTO1 • Adult ALL at AACR Annual Meeting 2019 • Pediatric ALL data at EHA-CAR T Conference ➢ AUTO3 • Pediatric ALL data update at R&D Day • Orphan drug designation for AUTO3 for Acute Lymphoblastic Leukemia (ALL) ➢ R&D Day 2019 • Highlighted modular approach to combat
Slide 8: AUTO1 is highly active with low rate of severe CRS
AUTO1 is highly active with low rate of severe CRS Key outcomes vs approved CD19-targeted therapies Pediatric ALL Adult ALL 1Kymriah- 2AUTO1 - pALL 3AUTO1 aALL 4Blinatumomab pALL Patient Numbers 75 14 10 271 CR Rate 81% 86% 88% 42% EFS EFS 12m: 50% EFS 12m: 46% tbd EFS 6m: 31% (95% CI, 35 to 64) (95
Slide 9: AUTO3 AMELIA interim efficacy data update Feb 2019
AUTO3 AMELIA interim efficacy data update Feb 2019 5x106/kg 15 12 11 3x106/kg 8 7 6 4* 3 0.3-2 x106/kg 2 1 Dose Patients 0 1 2 3 4 5 6 7 8 9 10 11 Duration (months) MRD neg CR Ongoing Relapse (PCR) Relapse (Flow) No Response (PCR) Response CD19 neg/pos disease due to prior CD19 CAR therapy, achieved
Slide 10: T cell therapies can be tailored to combat tumor complexity
T cell therapies can be tailored to combat tumor complexity Multiple properties can be incorporated through modular programming Advanced Targeting Pharmacological Control Enhanced Activity Modular approach enables rapid Our programs are designed to minimize innovation systemic toxicities observed wi
Slide 11: Examples of programming modules to enhance activity in solid tumors
Examples of programming modules to enhance activity in solid tumors Cytokine Signal dSHP2 dTGFβ Receptor Secreted Factor Constitutively active Truncated SHP2 to Truncated TGFβ A secreted factor to cytokine signal to block checkpoint Receptor to combat stimulate tumor overcome minimal upregulation hi
Slide 12: Additional operational highlights - Manufacturing
Additional operational highlights - Manufacturing ➢ CATAPULT facility operational in Stevenage, UK ➢ Initiated manufacturing for clinical studies in mid-March 2019 ➢ Plans for The GRiD (U.K.) and Rockville facility are progressing 12
Slide 13: Financial Results
Financial Results Andrew J. Oakley Chief Financial Officer 13
Slide 14: First quarter 2019 financial summary
First quarter 2019 financial summary USD m 1Q19 1Q18 Variance ➢ Follow on Grant Income 2.0 0.4 1.6 offering R&D (22.6) (11.6) (11.0) completed G&A (9.6) (4.3) (5.3) April 2019 • $109 m Operating Loss (30.2) (15.5) (14.7) aggregate net Other Income (0.4) (2.7) 2.3 proceeds raised (after UW Tax Benefi
Slide 15: Upcoming Milestones and Conclusion
Upcoming Milestones and Conclusion Dr. Christian Itin CEO and Chairman 15
Slide 16: Clinical newsflow expected through Q1 2020
Clinical newsflow expected through Q1 2020 Data could result in up to three Phase 2 trials within the next 12 months Program Q1-2 2019 Q3 2019 Q4 2019 Q1 2020 * AUTO1 – Adult ALL ** AUTO1 – Pediatric ALL AUTO2 - MM *** AUTO3 –Pediatric ALL AUTO3 – Adult DLBCL AUTO4 – T-Cell Lymphoma Multiple Next Ge
Slide 17: Q&A
Q&A Dr Christian Itin (CEO and Chairman) Andrew Oakley (CFO) Christopher Vann (COO) 17
Slide 18: Thank you.
Thank you. Autelus